Clinical Trials at Rhode Island Hospital
As of August 2026, 102 paid clinical trials are recruiting at Rhode Island Hospital, located at 593 EDDY ST, PROVIDENCE, RI 02903-4923, phone (401) 444-6966 in Providence, Rhode Island. Active studies at this site cover conditions such as Advanced Solid Tumor, Crohn's Disease and Endometrial Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Providence
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Verapamil Effect in Cystic Fibrosis-related Dysglycemia
104 clinical trials at Rhode Island Hospital
·Clear filters·A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Strategy for Improving Stroke Treatment Response
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
A Study of PYX-201 in Advanced Solid Tumors
Pilot/Pivotal Study of DBS+Rehab After Stroke
Study of SGR-1505 in Mature B-Cell Neoplasms
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Quality of End-of-Life Care for Children With Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Common conditions studied in Providence
- Advanced Solid Tumor (9 active studies)
- Crohn's Disease (8 active studies)
- Endometrial Cancer (8 active studies)
- Ulcerative Colitis (8 active studies)
- Acute Myeloid Leukemia (7 active studies)
- Alcohol Use Disorder (7 active studies)
Leading research sponsors in Providence
- Brown University
- Rhode Island Hospital
- National Cancer Institute (NCI)
- Women and Infants Hospital of Rhode Island
- Children's Oncology Group
Frequently asked questions
How many paid clinical trials are currently recruiting in Providence?
There are approximately 415 recruiting clinical trials in Providence, Rhode Island listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Providence pay participants?
Most recruiting trials in Providence compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Providence?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Providence?
The most common conditions under active study in Providence include Advanced Solid Tumor (9), Crohn's Disease (8), Endometrial Cancer (8), Ulcerative Colitis (8), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Providence?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Providence on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Providence?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Providence?
Recruiting research sites in Providence include Rhode Island Hospital, Brown University, Women and Infants Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Providence right now?
The largest active categories in Providence are Cancer & tumors (138), Neurology & pain (24), Cardiovascular (24). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Rhode Island Hospital?
Rhode Island Hospital is located at 593 EDDY ST, PROVIDENCE, RI 02903-4923. Use the Google Maps link in the intro above to get directions.
How do I contact Rhode Island Hospital?
You can reach Rhode Island Hospital by phone at (401) 444-6966. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.